Latest news with #CrownBioscience
Business Wire
07-05-2025
- Business
- Business Wire
Crown Bioscience Achieves Green Lab Sustainability Certification
SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, today announced that its facility in Leiden, Netherlands, has achieved the highest level of certification in the My Green Lab Certification program. This 'Green' level certification is the gold standard in laboratory sustainability best practices. Crown Bioscience Achieves Green Lab Sustainability Certification Share The My Green Lab Certification program, which is endorsed by the United Nations Race to Zero campaign, evaluated Crown Bioscience Netherlands across a range of sustainability metrics, including energy, water, waste, materials, recycling, and environmental engagement. After a thorough assessment, the lab earned a score of 81%—the highest level possible—demonstrating excellence and leadership in eco-friendly laboratory management. "We are thrilled to have our Netherlands site become the first My Green Lab certified location within Crown Bioscience," said Maria Radino, Vice President, Global Quality and Regulatory Compliance at Crown Bioscience. "This reflects the tremendous work our sustainability team has done to make our laboratories more environmentally responsible." The lab has implemented green initiatives to promote sustainability in several key areas. An administrative effort involved establishing a dedicated sustainability team to facilitate knowledge sharing and best practices throughout the organization. Sustainability has been integrated into the lab's documentation and training systems to reaffirm a long-term commitment to eco-friendly practices, including recycling and reducing plastic waste. Operationally, there has been a strong emphasis on equipment use, exploring new products with sustainable benefits, and promoting eco-friendly practices in water consumption and autoclave operations. The facility is taking steps to embed sustainability across its value chain by employing specific criteria in supplier selection and adopting a first in, first out (FIFO) inventory system to prevent product expiration and streamline ordering processes. Priority continues to focus on enhancing reagent and supply management, as well as sourcing biodegradable and environmentally safe products. By achieving this certification, Crown Bioscience is leading the way in building a culture of sustainability in the life sciences industry. The company is committed to expanding its sustainable lab practices to all locations worldwide. As a leading CRO, Crown Bioscience's certification demonstrates that environmental responsibility and world-class oncology research go hand in hand. Its Netherlands facility has set the sustainability bar high—defining what it means to be a green lab of the future. For more information on Crown Bioscience's certifications and accreditations, please click here. About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world's largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit
Business Wire
01-05-2025
- Business
- Business Wire
Crown Bioscience and NEXT Oncology Cement Partnership Extension
SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension of its partnership with NEXT Oncology, one of the world's largest Phase I Oncology Clinical Trial networks. This strategic partnership will continue to leverage Crown Bioscience's extensive experience in developing clinically relevant cancer organoid and patient-derived xenograft (PDX) models, together with NEXT Oncology's global clinical network and Phase I clinical trials expertise. Crown Bioscience and NEXT Oncology Cement Partnership Extension Share Through this extended agreement, Crown Bioscience reaffirms its exclusive rights to provide services based on patient samples sourced from NEXT Oncology's industry-leading global clinical trial network. This collaboration underscores Crown Bioscience's commitment to providing the most clinically relevant PDX and organoid models and solutions for translational oncology research. "We are thrilled to continue our exclusive partnership with NEXT Oncology," said John Gu, CEO of Crown Bioscience. "NEXT Oncology is globally recognized for its pioneering work in Phase I clinical oncology trials. Extending this partnership allows us to broaden our portfolio and strengthen our position as a leader in translational oncology platforms and integrated solutions. Our combined expertise and global reach will ensure rapid and scalable access to groundbreaking cancer models for our biopharma partners." 'NEXT Oncology is excited to continue our strong partnership with Crown Bioscience,' said Dr. Anthony Tolcher, CEO of NEXT Oncology. 'Together, we will continue to develop new and highly relevant patient models that Crown's biopharma partners can utilize to advance their translational oncology programs. Our combined efforts continue to support both companies' missions to help cancer patients receive the most advanced medicines possible.' About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world's largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit About NEXT Oncology NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT Oncology is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring medical oncologists. Texas Oncology is a practice within The US Oncology Network, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT Oncology unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.
Business Wire
28-04-2025
- Business
- Business Wire
AACR 2025: Crown Bioscience Unveils 3D Bone Marrow Niche
SAN DIEGO--(BUSINESS WIRE)--Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, today unveils at AACR 2025 its cutting-edge 3D bone marrow niche (BMN) in vitro models to advance hematological cancer research. Providing both the physical environment (cell-cell interactions), and the growth factor cocktail that hematological cancer cells require to thrive and proliferate, this innovative model provides a dynamic platform for studying liquid malignancies such as acute myeloid leukemia (AML) and multiple myeloma (MM). Crown Bioscience Unveils 3D Bone Marrow Niche In Vitro Models for Oncology Preclinical Screening in Hematological Malignancies Share The system incorporates key cellular components—stromal cells and endothelial cells—within biofunctional hydrogels seeded with patient-derived tumor cells, optionally supplemented with autologous immune cells. By accurately capturing the essential tumor microenvironment, the niche provides a physiologically relevant system that offers insight into tumor behavior, immune evasion, and drug resistance, outperforming classic suspension assays when it comes to cell viability, assay versatility, and clinical predictivity. 'Crown Bioscience is proud to unveil this high-content imaging-based 3D BMN platform that offers a unique and robust high-throughput drug screening in primary patient cells that allows testing of malignancies and toxicities at scale,' said Ludovic Bourré, Vice President, Research and Innovation, Crown Bioscience. 'Until now, bone marrow research has lagged behind solid tumor research due to lack of relevant in vitro models. With these BMN technological advances, we are now able to help researchers understand how cancer survives therapies once it reaches the bone marrow. This allows them to guide the selection of drug candidates with fewer off-target or bone marrow-related side effects and to overcome drug resistance mechanisms.' Researchers can realize significant benefits with the BMN models including: The use of more predictive ex vivo data to increase accuracy in cancer cell response The ability to screen compounds for hematological toxicity earlier in the drug development process Enhanced translational insight for more informed in vivo studies, helping to reduce animal use and speed up drug development Enabling the creation of more effective, targeted treatments through adhesion-mediated drug resistance modeling Unlocking new potential in stem cell, hematological malignancy, and bone-marrow-specific oncology studies The introduction of the BMN platform seamlessly integrates into Crown Bioscience's expertise in 3D organoid-like cell cultures, drug resistance models, and AML mouse models and bridges a gap between in vitro and in vivo models. Bourré said, 'This is a very exciting advancement for researchers and with this offering that integrates into Crown Bioscience's existing solutions, we're able to continually foster innovation and accelerate drug development.' Crown Bioscience will be presenting a poster at AACR, with details below. Title: 3D Bone Marrow Niche: Scalable and Physiologically Relevant Ex Vivo Drug Screening Platform for Acute Myeloid Leukemia and Multiple Myeloma Session Category: Experimental and Molecular Therapeutics Session Title: Drug Discovery Assay Technologies Session Date and Time: April 29 at 2:00PM CT Location: Poster section 16 Poster Board Number: 21 Published Abstract Number: 5493 To learn more about 3D BMN, visit our platform page. To view Crown Bioscience's poster, click here. About Crown Bioscience Crown Bioscience, a JSR Life Sciences company, is a global contract research organization (CRO) dedicated to accelerating drug discovery and development in oncology and immuno-oncology. We partner with biotech and pharmaceutical companies to provide innovative, tailored solutions spanning preclinical research, translational platforms, and clinical trial support. With the world's largest commercially available patient-derived xenograft (PDX) collection and approximately 1,000 tumor organoid models powered by Hubrecht Organoid Technology, we offer unparalleled insights across 35 cancer indications. Our expertise spans in vivo, in vitro, ex vivo, and in silico methods, complemented by advanced laboratory services that span the entire drug development continuum. Additionally, our extensive biobank of liquid and human biospecimens, complete with clinical histories, enhances oncology research capabilities. Operating from 11 state-of-the-art facilities across the US, Europe, and APAC, our laboratories meet the highest industry standards, including accreditation by the College of American Pathologists (CAP) and the International Organization for Standardization (ISO). To learn more, visit
